Agenda Summary Report (ASR)

Franklin County Board of Commissioners

DATE SUBMITTED: August 12, 2022	**PREPARED BY; Curtis McGary**
Meeting Date Requested: August 23, 2022	**PRESENTED BY:** Curtis Mc Gary
ITEM: (Select One) **x** Consent Agenda	☐ Brought Before the Board Time needed:
SUBJECT: SUBJECT: Purchase of Randox Evidence Multistat Blood analyzer Gold Services Contract . Service and Support Contract.	
FISCAL IMPACT: $6810.00	
BACKGROUND: BACKGROUND: Provide the Franklin County Coroner's office with a Randox Evidence Multistat blood drug analyzer, "Gold Service Contract". This will provide technical support and maintence service for the period of one year. This was not included in the original purchase of the Randox Evidence Multistat blood drug analyzer. The purchase of this equipment will be reimbursed 100% from the Washington State Patrol Federal Grant (Paul Coverdale Grant)	
RECOMMENDATION: Interbudget transfer of $6810. from current expense fund to Current Expense Coroner Department Budget Line 101220 Object 3122 Operating Supplies	
COORDINATION:	
ATTACHMENTS: (Documents you are submitting to the Board) **ATTACHMENTS: (Documents you are submitting to the Board)** **Resolution, Copy of Grant award. Randox Information sheet, Copy of Purchase invoice**	
HANDLING / ROUTING: (Once document is fully executed it will be imported into Document Manager. Please list name(s) of parties that will need a pdf)	

I certify the above information is accurate and complete.

Curtis McGary Coroner Name, Title

FRANKLIN COUNTY RESOLUTION _____

BEFORE THE BOARD OF COMMISSIONERS\
FRANKLIN COUNTY, WASHINGTON

Purchase of one Randox Evidence Multistat Analyzer
for Franklin County Coroner's Office

WHEREAS, The Franklin County Coroner's offices desires to purchase Gold Service Contract for the Randox Evidence Multistat Analyzer.

WHEREAS, The Purchase of the Randox Evidence Multistat Analyzer, Gold Service Contract will be reimbursed at 100% to the Franklin County Coroner's office from the Washington State Patrol Federal Grant Subrecipient Agreement.

WHEREAS, The purchase of the Randox Evidence Multistat Analyzer – Gold Service Contract will provide technical support and maintence service for the period of one year.

WHEREAS, the Board of Franklin County Commissioners constitutes the legislative authority of Franklin County and deems it in the best interest of Franklin County to purchase the Randox Evidence Multistat Analyzer, Gold Service Contract.

NOW, THEREFORE, BE IT RESOLVED the Board of County Commissioners for Franklin County does hereby approve the Purchase of one Randox Evidence Multistat Analyzer- Gold Service Contract.

APPROVED this ____ day of August 2022

BOARD OF COUNTY COMMISSIONERS
FRANKLIN COUNTY, WASHINGTON

_____
Chairman

_____
Chairman Pro Tem

_____
Member

ATTEST:

_____
Clerk to the Board

15 Industrial Boulevard
eameysville
/V 25430
SA

INVOICE

Original

Invoice No.:	49456
Invoice Date:	08/10/22
Due Date:	09/09/22
Customer No.:	796
Customer Ref. No.:	FCCO-0622

BILL TO	SHIP TO
Franklin County 1016 N 4th Ave Pasco WA 99301 USA	**Franklin County** 1016 N 4th Ave Pasco WA 99301 USA

Sales Employee: Khushbu Patel
Contact Name: AP
Terms: 30 Days From Invoice Date

Additional 1 yr Gold Service Contract
Contract dates are 18-Aug-2022 to 17-Aug-2023
Serial# TBD

TOTAL DUE $ 6,810.00
by 09/09/22

Item No.	Description	Discount %	Unit Price	Qty Shipped	Tota
EVGSC	Gold Service Contract	0.000	$ 6,810.00	1.000	$ 6,810.00

Subtotal	$ 6,810.00
Shipping	
Tax	
Total	$ 6,810.00
Deposit	
Balance Due	$ 6,810.00

PLEASE REMIT THIS AMOUN

Customer Account as of 08/10/22:
Balance: $ 55,766.68
Credit Limit: $ 0.00

Bank Details:
Bank of Charles Town
Routing No. 057001418
Account No. 033008538

If paying by Credit Card a 3% Processing Fee will be added to the balance of said PO/Invoice
If paying by ACH no additional fees will be charged

WASHINGTON STATE PATROL
FEDERAL GRANT SUBRECIPIENT AGREEMENT

WSP Agreement	K17890	Subrecipient Number	XXXX

FEDERAL GRANT

Federal Grant Award Name	CFDA Number(s)	Award Year
Paul Coverdell Forensic Science Improvement Grants Program – Formula	16.742	2021

Award Number	Awarding Agency	Award Amount	Performance Period
15BJA-21-GG-02938-COVE	US DOJ OJP BJA	$464,321.00	10/1/2021 – 9/30/2023

Is the Public Agency a subrecipient of federal assistance for the purposes of this agreement?	Is this agreement funded by a federal award for research and development?
☒ Yes ☐ No	☐ Yes ☒ No

WASHINGTON STATE PATROL (WSP)

WSP Project Director Name and Title	WSP Project Director Address
Ms. Mary Kellar FLSB CLD Quality Process Manager	WSP Forensic Lab Services 2203 Airport Way S #250 Seattle WA 98134-2028
Telephone 206-262-6005	**E-mail Address** Mary.kellar@wsp.wa.gov
WSP Administrative Contact Name and Title Mr. Simon Tee Chief Contracting Officer	**WSP Administrative Contact Address** WSP Budget and Fiscal Services PO Box 42602, Olympia WA 98504-2602
Telephone (360) 596-4052	**E-mail Address** Simon.Tee@wsp.wa.gov

SUBRECIPIENT

Public Agency Name	Statewide Vendor Registration Number
Franklin County Coroner's Office	SWV00 02298___ - ___
Location Address (zip+4) 1016 N 4th Avenue, Pasco, WA 99301-3706	**Mailing Address (zip+4)** (If different from location address)
Contact Name Curtis McGary	**DUNS: 70403969** **UEI:** __NLNDLYX3NLQ8_____
Contact Telephone (509) 546-5885 Office / (509) 537-4899 Cell	**Contact E-mail Address** cmcgary@franklincountywa.gov
Additional Public Agency Contact Name Insert	**E-mail Address** Insert

SUBAWARD

Start Date	End Date	Maximum Agreement Amount
May 1, 2022	September 30, 2023	$55,970.00

This Agreement, including the attached Terms and Conditions and any other documents incorporated by reference, contains all of the terms and conditions agreed upon by the parties. No other understandings or representations, oral or otherwise, regarding the subject matter of this Agreement shall be deemed to exist or bind the parties. The parties signing below warrant that they have read and understand this Agreement and have the authority to enter into this Agreement.

FOR THE WASHINGTON STATE PATROL:		FOR THE PUBLIC AGENCY:	
WSP Signature	Date	Public Agency Signature Curtis McGary D-ABMDI Digitally signed by Curtis McGary D-ABMDI DN: cn=Curtis McGary D-ABMDI, o=US, email=cmcgary@co.franklin.wa.us	Date 06/13/2022
Printed Name and Title John R. Batiste, Chief		Printed Name and Title Insert Curtis McGary	

STATEMENT OF WORK

1. **Introduction.** The purpose of this Agreement is to provide Fiscal Year 2021 (FY21) Paul Coverdell Forensic Science Improvement Grants Program – Formula grant funds to the Public Agency to improve forensic science and medical examiner/coroner services.

2. **Scope of Work.** As described in the Public Agency's FFY2021 Paul Coverdell – Formula proposal/application, the Public Agency will purchase a Drug analyzer and necessary supplies to save time and expense.

3. **Project Budget.** WSP shall reimburse the Federal Share of the following budget:

CATEGORY	ITEM	COST
EQUIPMENT	1x MultiSTAT Analyzer with installation, Training of 3 operators, Operators Manual, One year warranty	$48,230.00
	Shipping and handling of analyzer	
	Digital Centrifuge machine	
SUPPLIES	Evidence MultiSTAT Whole blood kit/Non Opiate Annual operating cost est.	$7,740.00
	SUBTOTAL: DIRECT COSTS	$55,970.00
	Indirect Costs	
TOTAL PROJECT COSTS		**$55,970.00**

Indirect may be charged for total direct costs. As a local government, the Public Agency is required to prepare and retain its indirect cost proposal on file for review. If applicable, Public Agency shall use the approved federally recognized indirect cost rate negotiated between the Public Agency and the Federal Government or, if no such rate exists, either a rate negotiated between the WSP and the Public Agency, or a de minimis indirect cost rate as defined in 2 C.F.R. 200.414(f).

The Public Agency Match may only be for allowable grant expenses. It is the Public Agency's responsibility to maintain records of the expenses used for match.

Expenditures may only occur within the categories listed above. Changes of up to 10 percent can be made without prior approval from WSP. Changes that exceed 10 percent will require the Public Agency to submit a budget change request to WSP for pre-approval.

4. **Equipment Management.**

   a. Title to Equipment. Upon successful completion of the terms of this Agreement, all equipment purchased by the Public Agency with Agreement funds will be owned by the Public Agency, or a recognized subrecipient for which a contract, subgrant agreement, or other means of legal transfer or ownership is in place.

   b. Use of Equipment. The Public Agency, or a recognized subrecipient, shall be responsible for

any and all operation, maintenance, replacement, and for the safe operation of the equipment, including all questions of liability.

c. Equipment Records. The Public Agency shall maintain Equipment records that include: a description of the Equipment; the manufacturer's serial number, model number, or other identification number, including the tag number; the source of the Equipment, including the Catalog of Federal Domestic Assistance (CFDA) number; who holds title; the acquisition date; the cost of the Equipment and the percentage of federal participation in the cost; the location, use and condition of the Equipment at the date the information was reported; and disposition data including the date of disposal and sale price of the Equipment. Equipment records shall be retained by the Public Agency for a period of six (6) years from the date of the disposition, replacement or transfer. If any litigation, claim, or audit is started before the expiration of the six year period, the records shall be retained by the Public Agency until all litigations, claims, or audit findings involving the records have been resolved. A copy of the Public Agency's record showing the above information of the purchased equipment is required when requesting reimbursement for the equipment.

d. Inventories. The Public Agency shall take a physical inventory of the Equipment and reconcile the results with the property records at least once every two years. Any differences between quantities determined by the physical inspection and those shown in the records shall be investigated by the Public Agency to determine the cause of the difference. The Public Agency shall, in connection with the inventory, verify the existence, current utilization, and continued need for the Equipment. The Public Agency shall develop a control system to ensure adequate safeguards to prevent loss, damage, and theft of the property. Any loss, damage or theft shall be investigated and a report generated. The Public Agency will develop adequate maintenance procedures to keep the property in good condition.

e. Disposition of Equipment. If the Public Agency is authorized or required to sell the property, proper sales procedures must be established to ensure the highest possible return. When original or replacement equipment is no longer needed for the original project or program or for other activities currently or previously supported by a federal agency, disposition of the equipment will be made as follows:

- Items of equipment with a current per-unit fair market value of less than $5,000 may be retained, sold or otherwise disposed of by the Public Agency with no further obligation to the awarding agency.

- Items of equipment with a current per-unit fair market value of more than $5,000 may be retained or sold and the Public Agency shall compensate the U.S. Department of Justice for its share. The Public Agency shall contact WSP before equipment is disposed.

5. Reports.

a. Semi-Annual Reports. The Public Agency shall submit to the WSP Project Manager semi-annual progress reports within 15 calendar days after the end of the reporting periods, which are January 1 - June 30 and July 1 - December 31, for the life of this Agreement. Reporting shall be in the format provided by WSP.

b. Final Report. The Public Agency shall submit a final report to the WSP Project Director at the completion of the Project, documenting all relevant project activities during the entire period of support under this Agreement. The Final Report shall be in the format provided by WSP and shall include a summary and assessment of the program carried out with this Agreement. The final report is due no later than 30 days at the completion of the Project and no later than 30 days following the close of the Agreement.

RANDOX

DRUGS OF ABUSE ARRAY BLOOD
—evidence—
MULTISTAT

INTENDED USE
The Evidence MultiSTAT DOA Blood Assays are tests for the qualitative determination of the parent molecule and metabolites of drugs in human whole blood. They are competitive enzyme immunoassays run on the automated biochip array analyser, Evidence MultiSTAT.

FOR FORENSIC USE ONLY. Not for use in diagnostic procedures

The Evidence MultiSTAT DOA Blood Assays provide only a preliminary analytical test result. A more specific alternative chemical method must be used to obtain a confirmed analytical result. Gas Chromatographyimass spectrometry (GC/MS) is the preferred confirmatory method[1]. Other chemical confirmation methods are available. Clinical consideration and professional judgement should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

Cat. No. EV4195
Containing the following components:

1.	Blood Test Cartridge	12 x 1 Cartridge
2.	Blood Cut Off	6 x 1 ml
3.	Blood Positive Control	4 x 1 ml
4.	Blood Sample Diluent	1x10ml
5.	Reconstitution Buffer	2 x 10 ml
6.	Sample Droppers	24 x Dropper

Cat. No. EV4116
Containing the following components:

1.	MultiSTAT Tip Cartridge	12 x 1 Tip Cartridge

CLINICAL SIGNIFICANCE
Drug abuse in any form gives rise to serious negative consequences, not only for the abuser by devastating their mental and physical health, but also to the whole of society. It is an indirect and direct cause of many crimes and also in the spread of diseases. It is very costly, with costs related to crime, medical care, treatment and welfare programs for addicted individuals and wasted working hours[1]. Blood drug testing can provide a tool for detecting users and for monitoring the compliance of subjects in recovery programs.

PRINCIPLE
The Evidence MultiSTAT analyser is a fully automated Biochip Array System. It performs simultaneous detection of multiple analytes from a single sample. The core technology is the Randox Biochip, a solid-state device containing an array of discrete test regions containing immobilized antibodies specific to different DOA compound classes. A competitive chemiluminescent immunoassay is employed for the DOA assays with the drug in the specimen and drug labelled with horseradish peroxidase (HRP) being in direct competition for the antibody binding sites. Increased levels of drug in a specimen will lead to reduced binding of drug labelled with HRP and thus a reduction in chemiluminescence being emitted.
The light signal generated from each of the test regions on the biochip is detected using digital imaging technology and compared to that from the cut off material. The classification of test analyte present in the sample is determined from the cut off material.

LIMITATIONS

Note: Please store MultiSTAT cartridges with label facing upwards.

- If this is not adhered to the integrity of the cartridge may be compromised and could impact on test results.
- Visually check the cartridge foil for evidence of moisture or damage to the foil seal.
- If there is any concern that the integrity of the cartridge has been compromised, do not use and contact Randox Toxicology Support.

- The Evidence MultiSTAT DOA Blood Array is designed for use only with human whole blood samples.
- There is a possibility that other substances and/or factors may interfere with the assays and cause erroneous results (e.g. technical or procedural errors).
- These assays have been designed to reduce HAMA and other heterophilic antibodies interference. However, HAMA and other heterophilic antibodies can react with the immunoglobulins included in the assay components. Clinical consideration and professional judgement should be applied to any drugs of abuse qualitative test result.

SPECIMEN COLLECTION AND PREPARATION
- The Evidence MultiSTAT DOA Blood Array is designed for use with human whole blood samples.
- Sample preparation should be carried out in accordance with the collection tube manufacturer's recommendations.
- **All whole blood samples should be centrifuged up to 13000 rpm (11000 G) for 10 minutes prior to the 4-fold dilution in sample diluent. Alternatively, 4000 rpm (1000 G) for 20 minutes can be used.**
- Whole blood samples should be diluted 4-fold in sample diluent prior to analysis, e.g. 150 µl sample + 450 µl sample diluent. The diluted sample is now ready for application to the MultiSTAT cartridge and should be analysed immediately following preparation.

SAMPLE STORAGE AND STABILITY
- If neat specimens are not to be analysed immediately, they should be frozen in small aliquots at –20°C. Repeat freeze/thaw cycles should be avoided.

SAFETY PRECAUTIONS AND WARNINGS
For *in vitro* human forensic use only. Do not pipette by mouth. Exercise the normal precautions required for handling laboratory reagents.

Wash buffer and Reconstitution buffer contain preservative. Avoid ingestion or contact with skin or mucous membranes.

Human samples should be handled and treated as if they are potentially infectious.

Please dispose of all biological and chemical materials according to local guidelines.

Health and Safety data sheets are available on request.

On opening the cartridge foil bag, visually check the cartridge for evidence of moisture and the cartridge foil for signs of tearing. If there is any concern that the integrity of the cartridge has been affected, do not use and contact Randox Toxicology Support.

REAGENT COMPOSITION

Contents

1. **MULTISTAT DOA BLOOD ASSAY DILUENT**
   20 mM phosphate buffer, pH 7.2, containing protein, detergents and preservatives. This is contained within the cartridge.

2. **MULTISTAT DOA BLOOD CONJUGATE**
   20 mM Tris based buffer, pH 7.0, containing protein, preservatives and horseradish peroxidase - labelled drug derivatives. This is contained within the cartridge.

3. **MULTISTAT DOA BLOOD BIOCHIP**
   Solid substrate containing immobilized antibody discrete test regions. This is contained within the cartridge.

4. **MULTISTAT DOA BLOOD WASH BUFFER**
   20 mM Tris buffered saline, pH 7.4, containing surfactant and preservatives. This is contained within the cartridge.

5. **LUM-EV934/PX**
   Luminol-EV934 and Peroxide are contained within the cartridge and are mixed in a ratio of 1:1 by the analyser to give the working signal reagent

6. **MULTISTAT DOA BLOOD CUT OFF**
   Lyophilised, 20 mM phosphate buffer, pH 7.2 containing stabilizers, preservatives and drug concentrations as outlined below.

7. **MULTISTAT DOA BLOOD POSITIVE CONTROL**
   Lyophilised, 20 mM phosphate buffer, pH 7.2 containing stabilizers, preservatives and drug concentrations as outlined below.

8. **MULTISTAT RECONSTITUTION BUFFER**
   A solution at a neutral pH containing preservatives.

9. **MULTISTAT DOA BLOOD SAMPLE DILUENT**
   20 mM phosphate buffer, pH 7.2 containing detergents and preservatives

STABILITY AND PREPARATION OF REAGENTS

1. **MULTISTAT DOA BLOOD TEST CARTRIDGE**
   The test cartridge is ready for use and is stable up to the expiry date when stored at +2°C to +8°C, protected from light. Test cartridges must be brought to room temperature for at least 30 minutes before opening. Once an individual test cartridge is open and out of its foil bag, it should be used for testing immediately.

2. **MULTISTAT DOA BLOOD CUT OFF**
   Lyophilised cut offs are stable until the expiry date when stored unopened, at +2 to +8°C. Gently tap the vial on the bench to ensure all material is at the bottom of the vial. Open the vial by partially removing the rubber stopper, avoiding any loss of material. Reconstitute in 1ml of accurately measured reconstitution buffer. Replace the rubber stopper and the close vial. After 2 minutes, swirl the vial gently and complete 3 quick inversions to ensure that all the material is dissolved, then leave upright for 30 minutes out of bright light before use. Following reconstitution ensure that the vial is stored upright and does not come in contact with the bung or plastics. Once reconstituted the cut off material is stable for 14 days when stored at +2 to +8°C.

3. **MULTISTAT DOA BLOOD POSITIVE CONTROL**
   Lyophilised positive controls are stable until the expiry date when stored unopened, at +2 to +8°C. Gently tap the vial on the bench to ensure all material is at the bottom of the vial. Open the vial by partially removing the rubber stopper, avoiding any loss of material. Reconstitute in 1ml of accurately measured reconstitution buffer. Replace the rubber stopper and the close vial. After 2 minutes, swirl the vial gently and complete 3 quick inversions to ensure that all the material is dissolved, then leave upright for 30 minutes out of bright light before use. Following reconstitution, ensure that the vial is stored upright and does not come in contact with the bung or plastics. Once reconstituted, the positive control material is stable for 14 days when stored at +2 to +8°.

4. **MULTISTAT RECONSTITUTION BUFFER**
   Reconstitution Buffer is ready for use and is stable up to the expiry date when stored at +2 to +8°C protected from light.

5. **MULTISTAT DOA BLOOD SAMPLE DILUENT**
   Sample diluent is ready to use and is stable up to the expiry date when stored at +2 to +8°C protected from light.

PROCEDURE

BATCH UPDATE FROM USB

Upon receipt of a new batch of EV4195, it is necessary to complete a batch-specific update from the USB provided:

- Scan the cartridge barcode – when scanned for the first time this will prompt the user to import the batch details from the provided USB.
- Insert the USB in to the USB port located on the bottom right hand side of the analyser below the power button.
- Once the USB has been connected select the import data button on screen.
- Select the batch update and select OK.
- A loading screen will appear briefly and the batch update will now be complete.
- For each batch, an initial 'Batch QC' must be run on the analyser, this will consist of running the provided Cut off and positive control material as indicated in the assay protocol section.

For further information please refer to the Evidence MultiSTAT Operators Manual.